In a large population-based study, high TG levels identified individuals at high CVD risk, who would not be definite eligible for statin treatment according to the 2016 ESC/EAS guidelines.
Deferral of therapy with ACE inhibitors, beta-blockers, and aldosterone antagonists for 1 year carries an absolute mortality risk of around 1% per month, which is higher than the mortality risk due to therapy mentioned in patient information leaflets.
In a meta-analysis of 13 observational studies, statin use was associated with a modest reduction in the risk of developing Parkinson’s Disease compared with not using statins.
In the UK Biobank, a slow self-reported walking pace was associated with a higher risk of all-cause and CV mortality in women and men, particularly in those with a low BMI.
Men with LDL-c levels ≥190 mg/dL without atherosclerotic CVD, have a 2-fold higher risk of major CV events than would be predicted with a risk calculator.
In a large retrospective cohort study, the risk of dementia was higher without oral anticoagulant treatment in patients with AF, compared with AF patients receiving oral anticoagulation.
AHA 2017 The new guidelines now define hypertension as >130/80 mmHg, emphasize the need for lifestyle changes and specify details of accurate BP measurement methods.
AHA 2017 A post-hoc survey of the SPRINT examined whether the presence or absence of physician or nursing in the BP measurement changed the treatment effect.
AHA 2017 A new analysis of CANTOS data shows that patients who achieved hsCRP <2 mg/L benefitted from a 25% reduction in MACE, irrespective of the dose of canakinumab.
Patients with SHTG treated with OM3-CA 2 g daily had a statistically significant reduction in TG and non-HDL-c concentrations compared with those treated with olive oil 2 g daily.
Differences in cognitive performance between diabetic patients and individuals with normal glucose levels can be explained by hyperglycemia and by BP-related variables, but not by insulin resistance.
This review summarizes the rationale to specifically target IL-1beta to lower residual inflammatory risk, now shown to be effective in the CANTOS trial. Other potential targets are also discussed.